The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...
The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...
Panelists discuss how the chronic nature of retinal diseases requires consistent VEGF suppression through regular anti-VEGF injections, but this treatment burden leads to challenges including patient ...
Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating ...
Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback